BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
News|Articles|September 18, 2026
From Direct-to-Patient to Direct-to-Disease: New Commercialization Models in Europe
Author(s)EVERSANA INTOUCH
The future of commercialization extends beyond product promotion and patient acquisition. Learn how Direct-to-Disease models enable pharmaceutical companies to build trusted, digitally enabled ecosystems that improve access, adherence, and long-term outcomes.
Related to this article
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Astellas gains an option on Audax’s IL-12 antibody-cytokine fusion DAX-044, while EVERSANA acquires London-based health economics firm Estima Scientific.
Shionogi’s Dr. Draica on why preventative antivirals matter — and how its HIV and flu prevention heritage shaped XOCOVA’s post-exposure focus.
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Brox.AI’s Hamish Brocklebank on three levels of digital clone use cases — from HCP content testing and GLP-1 price sensitivity modeling to simulating physician adoption after FDA approval.
Trending on PharmExec
1
The Next Biopharma Revolution: Quantum Computing
2
Roundup: Astellas Licenses IL-12 Fusion Protein From Audax in Deal Worth Up to $1.34 Billion, EVERSANA Acquires Health Economics Firm Estima Scientific
3
Rebuilding Clinical Data Workflows for the AI Era
4
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
5